FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular Dystrophy
06 janv. 2016 17h46 HE
|
FibroGen, Inc.
SAN FRANCISCO, Jan. 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) (“FibroGen”) announced today enrollment of the first two patients in an open-label, multicenter Phase 2 clinical...
Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2015 and Operational Progress
17 déc. 2015 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, Dec. 17, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Presents Additional Data From Phase 1b Modified Diet Clinical Trial of SMT C1100 in DMD Patients at WMS
30 sept. 2015 07h00 HE
|
Summit Therapeutics plc
10 of 12 Patients Achieved Plasma Concentrations Expected to Increase Utrophin Levels by Approximately 30% or Greater
Phase 2 Proof of Concept Trial Design Outlined, Expected to Initiate Q4...
Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2015 and Operational Progress
27 août 2015 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, Aug. 27, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics to Report Second Quarter 2015 Financial Results on 27 August 2015
24 août 2015 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, Aug. 24, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Announces Phase 1b Modified Diet Clinical Trial Achieves Primary Objective in Duchenne Muscular Dystrophy
17 août 2015 07h00 HE
|
Summit Therapeutics plc
Primary Objective Met; Plasma Absorption of SMT C1100 Observed at a Level Suitable for Further Development
SMT C1100 to Progress into Phase 2 Open-label Trial
Conference Call Scheduled...
Summit Therapeutics Reports First Quarter Results for the Three Months Ended 30 April 2015
11 juin 2015 07h00 HE
|
Summit Therapeutics plc
OXFORD, United Kingdom, June 11, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy
08 sept. 2014 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8,
2014 - Prosensa Holding N.V. (NASDAQ: RNA), the
biopharmaceutical company focusing on RNA-modulating...
Prosensa Awarded $200,000 Research Grant from PPMD
27 juin 2014 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, June 27, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
Prosensa Completes Enrollment in Natural History Study of Duchenne Muscular Dystrophy
25 juin 2014 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, June 25, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...